Étiquette : Epidiolex

The Impact of Cannabidiol on Psychiatric and Medical Conditions, Thersilla Oberbarnscheidt & Norman S. Miller, 2019

The Impact of Cannabidiol on Psychiatric and Medical Conditions Thersilla Oberbarnscheidt, Norman S. Miller Journal of Clinical and Medical Research, 2020, 12, (7), 393-403. Doi : 10.14740/jocmr4159   Abstract Cannabidiol (CBD) is a substance chemically derived from Cannabis sativa and discussed to be non-psychoactive. According to the FDA, marijuana is classified as a schedule I substance; however, hemp which is defined as extracts from marijuana including cannabinoids containing less than 0.3% tetrahydrocannabinol (THC), is excluded from that controlled substance act and available at local convenience stores in the US as it is seen as an herbal supplement. CBD is purported to be used for various medical [...]

Lire la suite

Etats-Unis : l’Epidiolex n’est plus une substance contrôlée, Aurélien BERNARD, 2020

Etats-Unis : l’Epidiolex n’est plus une substance contrôlée Aurélien BERNARD Newsweed.fr, 8 avril 2020   https://www.newsweed.fr/etats-unis-lepidiolex-nest-plus-une-substance-controlee/     GW Pharmaceuticals a annoncé lundi que l’Epidiolex, un médicament à base de cannabidiol (CBD) utilisé dans le traitement de l’épilepsie, avait été retiré de l’annexe V de la Loi américaine sur les substances contrôlées par la Drug Enforcement Administration (DEA). Les personnes qui pourraient en bénéficier pourront dorénavant en obtenir plus facilement. GW a déclaré dans son communiqué qu’il « entamera maintenant le processus de mise en œuvre de ces changements au niveau de l’État et via le réseau de distribution EPIDIOLEX ». Comme pour de nombreux médicaments non-contrôlés, les malades ou leurs [...]

Lire la suite

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial, Kerri A. Schoedel et al., 2018

Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users : A randomized, double-blind, controlled trial Kerri A. Schoedel, Isabella Szeto, Beatrice Setnik, Edward M. Sellers, Naama Levy-Cooperman, Catherine Mills, Tilden Etges, Kenneth Sommerville Epilepsy & Behavior, 2018, 88, 162–171. Doi : 10.1016/j.yebeh.2018.07.027   a b s t r a c t Rationale : Treatment with a highly purified oral solution of cannabidiol (CBD), derived from the plant Cannabis sativa L., demonstrated some evidence of central nervous system (CNS)-related adverse events in patients enrolled in phase 3 trials for treatment of childhood-onset epilepsy. Cannabidiol was categorized as a Schedule 1 substance by the United States Drug [...]

Lire la suite

Le cannabidiol, un agent thérapeutique prometteur ?, Benjamin Rolland et al., 2019

Le cannabidiol, un agent thérapeutique prometteur ? Benjamin Rolland , Mathieu Chappuy, Patrizia Carrieri SWAPS, 3e et 4e trimestre 2019, n° 92-93, , 5-6.   Deuxième cannabinoïde le plus étudié après le THC, sans effet psychoactif, le cannabidiol dispose de propriétés thérapeutiques intéressantes, notamment en psychiatrie. Le point sur les recherches La grande famille des cannabinoïdes Les cannabinoïdes sont un ensemble de substances capables d’activer les récepteurs du même nom (« récepteurs cannabinoïdes »). Il existe deux grandes familles de récepteurs cannabinoïdes, CB1 et CB2. Dans le système nerveux central, c’est surtout CB1 qui est exprimé, alors que CB2 est principalement présent dans le système immunitaire. [...]

Lire la suite

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans, Sophie A. Millar et al., 2018

A Systematic Review on the Pharmacokinetics of Cannabidiol in Humans Sophie A. Millar, Nicole L. Stone, Andrew S. Yates  and Saoirse E. O’Sullivan Frontiers in  Pharmacology, 26 November 2018 https://doi.org/10.3389/fphar.2018.01365 Background : Cannabidiol is being pursued as a therapeutic treatment for multiple conditions, usually by oral delivery. Animal studies suggest oral bioavailability is low, but literature in humans is not sufficient. The aim of this review was to collate published data in this area. Methods : A systematic search of PubMed and EMBASE (including MEDLINE) was conducted to retrieve all articles reporting pharmacokinetic data of CBD in humans. Results : Of 792 articles retireved, 24 included [...]

Lire la suite

Trends in Internet Searches for Cannabidiol (CBD) in the United States, Eric C. Leas et al., 2019

Trends in Internet Searches for Cannabidiol (CBD) in the United States Eric C. Leas, Alicia L. Nobles, PhD, Theodore L. Caputi, Mark Dredze, DaveyM. Smith, JohnW. Ayers JAMA Network Open, 2019, 2, (10), e1913853. doi: 10.1001/jamanetworkopen.2019.13853   Introduction Cannabidiol (CBD) is widely promoted as a panacea. For example, the cannabis brand MedMen claims CBD treats acne, anxiety, opioid addiction, pain, and menstrual problems.1 However, the US Food and Drug Administration has only approved highly purified CBD (Epidiolex) for treating epilepsy. To our knowledge, there is currently no population-focused surveillance of public interest in CBD. Consequently, many question whether CBD should be prioritized by public health leaders [...]

Lire la suite

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study, Darren Reithmeier et al., 2018

The protocol for the Cannabidiol in children with refractory epileptic encephalopathy (CARE-E) study : a phase 1 dosage escalation study Darren Reithmeier, Richard Tang-Wai, Blair Seifert, Andrew W. Lyon, Jane Alcorn, Bryan Acton, Scott Corley, Erin Prosser-Loose, Darrell D. Mousseau, Hyun J. Lim, Jose Tellez-Zenteno, Linda Huh, Edward Leung, Lionel Carmant and Richard J. Huntsman BMC Pediatrics, 2018, 18:221 https://doi.org/10.1186/s12887-018-1191-y   Abstract Background : Initial studies suggest pharmaceutical grade cannabidiol (CBD) can reduce the frequency of convulsive seizures and lead to improvements in quality of life in children affected by epileptic encephalopathies. With limited access to pharmaceutical CBD, Cannabis extracts in oil are becoming increasingly available. [...]

Lire la suite

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome, Bin GU et al., 2019 model mice,

Cannabidiol attenuates seizures and EEG abnormalities in Angelman syndrome model mice. Bin Gu, Manhua Zhu, Madison R. Glass, Marie Rougié, Viktoriya D. Nikolova, Sheryl S. Moy, Paul R. Carney, and Benjamin D. Philpot Journal of Clinical Investigation, 2019 Sep 10, pii: 130419. doi : 10.1172/JCI130419 PMID : 31503547 Abstract Angelman syndrome (AS) is a neurodevelopmental disorder characterized by intellectual disability, lack of speech, ataxia, EEG abnormalities, and epilepsy. Seizures in AS individuals are common, debilitating, and often drug-resistant. Therefore, there is an unmet need for better treatment options. Cannabidiol (CBD), a major phytocannabinoid constituent of cannabis, has antiseizure activity and behavioral benefits in preclinical and [...]

Lire la suite

EC Clears Cannabidiol for Severe Forms of Epilepsy – Medscape -Deborah Brauser,  Sep 23, 2019.

EC Clears Cannabidiol for Severe Forms of Epilepsy Deborah Brauser Medscape Medical News © September 23, 2019   The European Commission (EC) has approved the add-on use of cannabidiol oral solution (Epidyolex, GW Pharmaceuticals) for treating seizures associated with two severe forms of epilepsy, the manufacturer reports. The indication for the drug in the EC's marketing authorization is for use as adjunctive therapy with clobazam (multiple brands) in patients ages 2 and older who have Lennox-Gastaut syndrome (LGS) or Dravet syndrome. As reported by Medscape Medical News, the European Medicine's Agency's (EMA's) Committee for Medicinal Products for Human Use recommended approval for the drug in July. A year earlier, [...]

Lire la suite

Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model, Laura E. Ewing et al., 2019

Hepatotoxicity of a Cannabidiol-Rich Cannabis Extract in the Mouse Model Laura E. Ewing, Charles M. Skinner, Charles M. Quick, Stefanie Kennon-McGill, Mitchell R. McGill, Larry A. Walker, Mahmoud A. ElSohly, Bill J. Gurley and Igor Koturbash Molecules, 2019, 24, 1694 doi : 10.3390/molecules24091694 Abstract : The goal of this study was to investigate Cannabidiol (CBD) hepatotoxicity in 8-week-old male B6C3F1 mice. Animals were gavaged with either 0, 246, 738, or 2460 mg/kg of CBD (acute toxicity, 24 h) or with daily doses of 0, 61.5, 184.5, or 615 mg/kg for 10 days (sub-acute toxicity). These doses were the allometrically scaled mouse equivalent doses (MED) [...]

Lire la suite